New cocktail attack on rare cancers shows promise in early trial
NCT ID NCT06232564
First seen Jan 26, 2026 · Last updated Jun 18, 2026 · Updated 29 times
Summary
This study tests a combination of chemotherapy (etoposide and carboplatin) plus an immunotherapy drug (pembrolizumab) followed by two maintenance drugs (pembrolizumab and lenvatinib) in 20 people with advanced high-grade neuroendocrine tumors who have not had chemotherapy before. The goal is to see if this approach shrinks tumors and is safe. This is an early-phase trial, so results will guide future research rather than offer a cure.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEUROENDOCRINE TUMORS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Imperial College Healthcare NHS Trust
London, W12 0HS, United Kingdom
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.